Table 1.

Baseline characteristics of the entire cohort (N = 35)

CharacteristicValue
Age, median (range), y 67 (38-78) 
Male 24 (69%) 
Race, white 35 (100%) 
ECOG performance status score  
 0 16 (46%) 
 1 17 (49%) 
 2 2 (6%) 
Eligible for autologous stem cell transplant 29 (85%) 
Involved organs  
 Cardiac 23 (66%) 
 Renal 19 (54%) 
 Nerve 6 (17%) 
 Hepatic 4 (11%) 
 >1 organ 15 (43%) 
Lambda restricted 26 (74%) 
BMPCs, median (range), % 9 (<5%-30%) 
dFLC, median (range), mg/dL 29.0 (5.0-109) 
Serum creatinine, median (range), mg/dL 1.1 (0.6-1.9) 
2012 Mayo AL amyloidosis stage, I/II/III/IV, % 20/31.4/22.9/25.7 
FISH abnormalities (n = 28)*  
 t(11;14) 50% 
 del(13q)/monosomy 13 43% 
 Trisomies 32% 
 gain(1q) 14% 
 del(17p)/monosomy 17 11% 
 t(4;14) 4% 
 t(14;20) 4% 
 >1 abnormality 61% 
CharacteristicValue
Age, median (range), y 67 (38-78) 
Male 24 (69%) 
Race, white 35 (100%) 
ECOG performance status score  
 0 16 (46%) 
 1 17 (49%) 
 2 2 (6%) 
Eligible for autologous stem cell transplant 29 (85%) 
Involved organs  
 Cardiac 23 (66%) 
 Renal 19 (54%) 
 Nerve 6 (17%) 
 Hepatic 4 (11%) 
 >1 organ 15 (43%) 
Lambda restricted 26 (74%) 
BMPCs, median (range), % 9 (<5%-30%) 
dFLC, median (range), mg/dL 29.0 (5.0-109) 
Serum creatinine, median (range), mg/dL 1.1 (0.6-1.9) 
2012 Mayo AL amyloidosis stage, I/II/III/IV, % 20/31.4/22.9/25.7 
FISH abnormalities (n = 28)*  
 t(11;14) 50% 
 del(13q)/monosomy 13 43% 
 Trisomies 32% 
 gain(1q) 14% 
 del(17p)/monosomy 17 11% 
 t(4;14) 4% 
 t(14;20) 4% 
 >1 abnormality 61% 

BMPC, bone marrow plasma cells; dFLC, difference between involved to uninvolved light chains; ECOG, Eastern Cooperative Oncology Group.

*

Four patients had insufficient clonal plasma cells for testing; 3 patients did not have fluorescence in situ hybridization (FISH) testing performed.

or Create an Account

Close Modal
Close Modal